Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
976 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03993353 | Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 7 | University of California, San DiegoOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT01932697 | Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer | completed | Phase 2 | 81 | Mayo ClinicOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC. |
| completed |
| — |
| 1,197 |
| Fudan UniversityOTHER |
| 1 |
| Feb 5, 2026 |
| clinicaltrials |
| NCT04284540 | Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma | completed | N/A | 37 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT03082534 | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of California, San DiegoOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07085845 | The Self-Sampling Pilot Study(SOLOPilot) | completed | N/A | 50 | Medical College of WisconsinOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07363629 | Impact of Preserving Versus Ligating the Right Gastric Artery on Anastomotic Outcomes After McKeown Esophagectomy: A Randomized Controlled Trial | completed | N/A | 120 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03829722 | Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | completed | Phase 2 | 26 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03978689 | A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 80 | Cue BiopharmaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03578406 | HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer | completed | Phase 1 | 9 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03889912 | Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma | completed | Phase 1 | 97 | Regeneron PharmaceuticalsINDUSTRY | 3 | Jan 21, 2026 | clinicaltrials |
| NCT05524025 | The SPOT-HPV Study | completed | — | 360 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04139057 | EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC | completed | Phase 1 / Phase 2 | 10 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07337122 | Collagen Matrix in Oral Cancer Surgery | completed | — | 33 | SAYAH CharlineOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04326257 | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | completed | Phase 2 | 20 | Dan ZandbergOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05482880 | Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region | completed | — | 78 | Maastricht University Medical CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03896412 | Detection of Circulating Tumor DNA in p16- Locally Advanced Head Neck Squamous Cell Carcinoma(PERSO-NECK) | completed | N/A | 40 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04031534 | Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma(HYPONECK) | completed | Phase 2 | 16 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02131805 | Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma | completed | N/A | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04490564 | Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma | completed | — | 135 | Pharmassist LtdINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT01827956 | Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms(FCR-VADS) | completed | — | 121 | Institut BergoniéOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT04045496 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT04154943 | Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 79 | Regeneron PharmaceuticalsINDUSTRY | 3 | Dec 23, 2025 | clinicaltrials |
| NCT03509467 | Using MC1R Genotype to Impact Melanoma Risk Behavior | completed | N/A | 2,054 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 2 | Dec 19, 2025 | clinicaltrials |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04811027 | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC(TACTI-003) | completed | Phase 2 | 171 | Immutep S.A.S.INDUSTRY | 9 | Dec 11, 2025 | clinicaltrials |
| NCT03177291 | Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC | completed | Phase 1 | 48 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03381183 | IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06730412 | ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)(Clear-HPVca) | completed | — | 103 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04974047 | Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma(RATIONALE-213) | completed | Phase 2 | 70 | BeiGeneINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05383170 | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers(Catalyst) | completed | Phase 1 / Phase 2 | 6 | Cytovation ASINDUSTRY | 5 | Nov 28, 2025 | clinicaltrials |
| NCT04725396 | Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC(CURVE) | completed | N/A | 132 | UNICANCEROTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04454489 | Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition | completed | Phase 2 | 21 | Wake Forest University Health SciencesOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07236320 | Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC | completed | N/A | 200 | Yongtao HanOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT02369458 | Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies | completed | Phase 2 | 48 | Washington University School of MedicineOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02442375 | Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity(UPGRADE-RT) | completed | Phase 3 | 300 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03021993 | Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer | completed | Phase 2 | 17 | Medical University of South CarolinaOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03738228 | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03049618 | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | completed | Phase 2 | 42 | University of Southern CaliforniaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT03836105 | CemiplimAb Survivorship Epidemiology(CASE) | completed | — | 287 | Regeneron PharmaceuticalsINDUSTRY | 2 | Oct 15, 2025 | clinicaltrials |
| NCT02586207 | Pembrolizumab in Combination With CRT for LA-SCCHN | completed | Phase 1 | 59 | Sanford HealthOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT04215978 | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 204 | BeiGeneINDUSTRY | 8 | Oct 3, 2025 | clinicaltrials |
| NCT01644786 | The Head and Neck Tumor Biobank | completed | — | 419 | Maastricht Radiation OncologyOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06192212 | PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive Esophagectomy | completed | — | 577 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04260126 | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC(VERSATILE002) | completed | Phase 2 | 95 | PDS Biotechnology Corp.INDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Feb 12, 2026source: clinicaltrials